Abstract
Currently treatment of HIV-1 infected patients consists of combination therapy with antiretroviral agents from three different classes (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors). Although combination therapy with these agents leads to a strong reduction in morbidity and mortality, the occurrence of side effects and the development of resistance limits the long term use of these agents. Therefore, there is a strong demand for new antiretroviral agents with a new target in virus replication. One of the most promising new groups consists of the fusion inhibitors. These compounds inhibit the fusion of HIV with the host cell and, therefore, prevent infection of the host cell. Currently, several compounds, which inhibit the fusion process at several stages, are in development. This article provides a concise overview of these compounds.
Translated title of the contribution | HIV adsorption and fusion inhibitors. A new way of drug targeting in the process of virus replication |
---|---|
Original language | Dutch |
Pages (from-to) | 796-801 |
Number of pages | 6 |
Journal | Pharmaceutisch Weekblad |
Volume | 137 |
Issue number | 22 |
Publication status | Published - 31 May 2002 |
Externally published | Yes |